The elevated expression of CDCP1 on the surface of malignant cells has led to its investigation in pre-clinical models as a target for monoclonal antibodies (mAbs) that have therapeutic potential against prostate, breast and epithelial ovarian cancer (EOC) 9-12, 15, 20-24. The gene discussed is CDCP1; the disease is ovarian carcinoma.